BioWorld

Jan. 28, 2005

Amgen Reports Higher Revenues, Sales; Earnings Below Estimates

Despite experiencing a 24 percent increase in product sales and a 26 percent increase in adjusted earning, Amgen Inc. missed its earning expectations for the fourth quarter. (BioWorld Today) Read More

Ariad, Stent Company Medinol In Partnership Worth Up To $40M

Theravance Begins Second Phase III Trial For Telavancin

Zonagen Brings In $17.6M To Push Progenta, Androxal Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 30, 2026.

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026